[1]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
|
[2]
|
Siegel, R.L., Miller, K.D., Fuchs, H.E., et al. (2021) Cancer Statistics, 2021. CA: A Cancer Journal for Clinicians, 71, 7-33. https://doi.org/10.3322/caac.21654
|
[3]
|
Chi, F., Wu, R., Jin, X., et al. (2016) HER2 Induces Cell Proliferation and Invasion of Non-Small-Cell Lung Cancer by Upregulating COX-2 Expression via MEK/ERK Signaling Pathway. OncoTargets and Therapy, 9, 2709-2716.
https://doi.org/10.2147/OTT.S96197
|
[4]
|
Riudavets, M., Sullivan, I., Abdayem, P., et al. (2021) Targeting HER2 in Non-Small-Cell Lung Cancer (NSCLC): A Glimpse of Hope? An Updated Review on Therapeutic Strategies in NSCLC Harbouring HER2 Alterations. ESMO Open, 6, Article ID: 100260. https://doi.org/10.1016/j.esmoop.2021.100260
|
[5]
|
Aix, S.P., Navarro, A., Bernabe, R., et al. (2021) 464 2SMALL (Nct04253145) Phase I Part: Lurbinectidine (Lur) in Combination with Atezolizumab (Atz) for Second Line Extensive Stage Small Cell Lung Cancer (Es-Sclc) Patients (Pts). Journal for Immunotherapy of Cancer, 9, A493. https://doi.org/10.1136/jitc-2021-SITC2021.464
|
[6]
|
Barlesi, F., Mazieres, J., Merlio, J.P., et al. (2016) Routine Molecular Profiling of Patients with Advanced Non-Small-Cell Lung Cancer: Results of a 1-Year Nationwide Pro-gramme of the French Cooperative Thoracic Intergroup (IFCT). The Lancet, 387, 1415-1426. https://doi.org/10.1016/S0140-6736(16)00004-0
|
[7]
|
Yang, G., Yang, Y., Liu, R., et al. (2022) First-Line Immu-notherapy or Angiogenesis Inhibitor plus Chemotherapy for HER2-Altered NSCLC: A Retrospective Real-World POLISH Study. Therapeutic Advances in Medical Oncology, 14.
https://doi.org/10.1177/17588359221082339
|
[8]
|
Zhou, J., Hu, J., Song, Y., et al. (2020) Clinical Outcomes of Patients with HER2-Mutant Advanced Lung Cancer: Chemotherapies versus HER2-Directed Therapies. American Jour-nal of Respiratory and Critical Care Medicine, 201, A2455. https://doi.org/10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A2455
|
[9]
|
Wang, Y., Zhang, S.J., Wu, F.Y., et al. (2018) Outcomes of Pemetrexed-Based Chemotherapies In-Mutant Lung Cancers. BMC Cancer, 18, Article No. 326. https://doi.org/10.1186/s12885-018-4277-x
|
[10]
|
Lewis Phillips, G.D., Li, G., Dugger, D.L., et al. (2008) Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1: An Antibody-Cytotoxic Drug Conjugate. Cancer Re-search, 68, 9280-9290.
https://doi.org/10.1158/0008-5472.CAN-08-1776
|
[11]
|
De Langen, A.J., Jebbink, M., Hashemi, S.M.S., et al. (2018) Trastuzumab and Paclitaxel in Patients with EGFR Mutated NSCLC That Express HER2 after Progression on EGFR TKI Treatment. British Journal of Cancer, 119, 558-564. https://doi.org/10.1038/s41416-018-0194-7
|
[12]
|
Li, B.T., Shen, R., Buonocore, D., et al. (2018) Ado-Trastuzumab Emtansine for Patients with HER2-Mutant Lung Cancers: Results from a Phase II Basket Trial. Journal of Clinical On-cology: Official Journal of the American Society of Clinical Oncology, 36, 2532-2537. https://doi.org/10.1200/JCO.2018.77.9777
|
[13]
|
Iwama, E., Zenke, Y., Sugawara, S., et al. (2022) Trastuzumab Emtansine for Patients with Non-Small Cell Lung Cancer Positive for Human Epidermal Growth Factor2 Exon-20 Inser-tion Mutations. European Journal of Cancer, 162, 99-106. https://doi.org/10.1016/j.ejca.2021.11.021
|
[14]
|
Hotta, K., Aoe, K., Kozuki, T., et al. (2018) A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 13, 273-279. https://doi.org/10.1016/j.jtho.2017.10.032
|
[15]
|
Peters, S., Stahel, R., Bubendorf, L., et al. (2019) Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers. Clinical Cancer Re-search, 25, 64-72. https://doi.org/10.1158/1078-0432.CCR-18-1590
|
[16]
|
Ogitani, Y., Aida, T., Hagihara, K., et al. (2016) DS-8201a, a Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Prom-ising Antitumor Efficacy with Differentiation from T-DM1. Clinical Cancer Research, 22, 5097-5108. https://doi.org/10.1158/1078-0432.CCR-15-2822
|
[17]
|
Ogitani, Y., Hagihara, K., Oitate, M., et al. (2016) Bystand-er Killing Effect of DS-8201a, a Novel Anti-Human Epidermal Growth Factor Receptor 2 Antibody-Drug Conjugate, in Tumors with Human Epidermal Growth Factor Receptor 2 Heterogeneity. Cancer Science, 107, 1039-1046. https://doi.org/10.1111/cas.12966
|
[18]
|
Tsurutani, J., Iwata, H., Krop, I., et al. (2020) Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors. Cancer Discovery, 10, 688-701.
https://doi.org/10.1158/2159-8290.CD-19-1014
|
[19]
|
Li, B.T., Smit, E.F., Goto, Y., et al. (2022) Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 386, 241-251. https://doi.org/10.1056/NEJMoa2112431
|
[20]
|
Goto, K., Goto, Y., Kubo, T., et al. (2023) Trastuzumab Deruxtecan in Patients with HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results from the Randomized, Phase II DESTINY-Lung02 Trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 41, 4852-4863.
|
[21]
|
Klapper, L.N., Waterman, H., Sela, M., et al. (2000) Tumor-Inhibitory Antibodies To HER-2/ErbB-2 May Act by Recruiting C-Cbl and Enhancing Ubiquitination of HER-2. Cancer Research, 60, 3384-3388.
|
[22]
|
Zinner, R.G., Glisson, B.S., Fossella, F.V., et al. (2004) Trastuzumab in Combination with Cisplatin and Gemcitabine in Patients with Her2-Overexpressing, Untreated, Advanced Non-Small Cell Lung Cancer: Report of A Phase II Trial and Findings Regarding Optimal Identification of Patients with Her2-Overexpressing Disease. Lung Can-cer, 44, 99-110. https://doi.org/10.1016/j.lungcan.2003.09.026
|
[23]
|
Gatzemeier, U., Groth, G., Butts, C., et al. (2004) Randomized Phase II Trial of Gemcitabine-Cisplatin with or without Trastuzumab in HER2-Positive Non-Small-Cell Lung Cancer. Annals of Oncology, 15, 19-27.
https://doi.org/10.1093/annonc/mdh031
|
[24]
|
Lara, P.N., Laptalo, L., Longmate, J., et al. (2004) Trastuzumab plus Docetaxel in HER2/Neu-Positive Non-Small-Cell Lung Cancer: A California Cancer Consortium Screening and Phase II Trial. Clinical Lung Cancer, 5, 231-236.
https://doi.org/10.3816/CLC.2004.n.004
|
[25]
|
Langer, C.J., Stephenson, P., Thor, A., et al. (2004) Trastuzumab in the Treatment of Advanced Non-Small-Cell Lung Cancer: Is There a Role? Focus on Eastern Cooperative Oncology Group Study 2598. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 22, 1180-1187.
https://doi.org/10.1200/JCO.2004.04.105
|
[26]
|
Mazières, J., Barlesi, F., Filleron, T., et al. (2016) Lung Cancer Pa-tients with HER2 Mutations Treated with Chemotherapy and HER2-Targeted Drugs: Results from the European EUHER2 Cohort. Annals of Oncology, 27, 281-286.
https://doi.org/10.1093/annonc/mdv573
|
[27]
|
Hainsworth, J.D., Meric-Bernstam, F., Swanton, C., et al. (2018) Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results from MyPathway, an Open-Label, Phase IIa Multiple Basket Study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 36, 536-542.
https://doi.org/10.1200/JCO.2017.75.3780
|
[28]
|
Mazieres, J., Lafitte, C., Ricordel, C., et al. (2022) Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients with Advanced Non-Small-Cell Lung Cancer Harboring HER2 Mutations: Results from the IFCT-1703 R2D2 Trial. Journal of Clinical Oncology: Official Journal of the American So-ciety of Clinical Oncology, 40, 719-728.
https://doi.org/10.1200/JCO.21.01455
|
[29]
|
Wang, Y., Jiang, T., Qin, Z., et al. (2019) HER2 Exon 20 Insertions in Non-Small-Cell Lung Cancer Are Sensitive to the Irreversible Pan-HER Receptor Tyrosine Kinase Inhibitor Pyrotinib. Annals of Oncology, 30, 447-455.
https://doi.org/10.1093/annonc/mdy542
|
[30]
|
Zhou, C., Li, X., Wang, Q., et al. (2020) Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma after Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 38, 2753-2761. https://doi.org/10.1200/JCO.20.00297
|
[31]
|
Song, Z.B., Lv, D.Q., Chen, S.Q., et al. (2022) Pyrotinib in Patients with HER2-Amplified Advanced Non-Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial. Clinical Cancer Research, 28, 461-467.
https://doi.org/10.1158/1078-0432.CCR-21-2936
|
[32]
|
Song, Z., Li, Y., Chen, S., et al. (2022) Efficacy and Safety of Pyrotinib in Advanced Lung Adenocarcinoma with HER2 Mutations: A Multicenter, Single-Arm, Phase II Trial. BMC Medicine, 20, Article No. 42.
https://doi.org/10.1186/s12916-022-02245-z
|
[33]
|
Liu, S.M., Tu, H.Y., Wei, X.W., et al. (2023) First-Line Pyro-tinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer: A Patient-Centric Phase 2 Trial. Nature Medicine, 29, 2079-2086. https://doi.org/10.1038/s41591-023-02461-x
|
[34]
|
Yang, G., Xu, H., Yang, Y., et al. (2022) Pyrotinib Combined with Apatinib for Targeting Metastatic Non-Small Cell Lung Cancer with HER2 Alterations: A Prospective, Open-Label, Single-Arm Phase 2 Study (PATHER2). BMC Medicine, 20, Article No. 277. https://doi.org/10.1186/s12916-022-02470-6
|
[35]
|
Ai, X., Song, Z., Jian, H., et al. (2021) Pyrotinib Combined with Thalidomide in Advanced Non-Small-Cell Lung Cancer Patients Harboring HER2 Exon 20 Insertions (PRIDE): Protocol of an Open-Label, Single-Arm Phase II Trial. BMC Cancer, 21, Article No. 1033. https://doi.org/10.1186/s12885-021-08759-8
|
[36]
|
Robichaux, J.P., Elamin, Y.Y., Tan, Z., et al. (2018) Mecha-nisms and Clinical Activity of an EGFR and HER2 Exon 20-Selective Kinase Inhibitor in Non-Small Cell Lung Cancer. Nature Medicine, 24, 638-646.
https://doi.org/10.1038/s41591-018-0007-9
|
[37]
|
Koga, T., Kobayashi, Y., Tomizawa, K., et al. (2018) Activity of a Novel HER2 Inhibitor, Poziotinib, for HER2 Exon 20 Mutations in Lung Cancer and Mechanism of Acquired Re-sistance: An in Vitro Study. Lung Cancer, 126, 72-79.
https://doi.org/10.1016/j.lungcan.2018.10.019
|
[38]
|
Robichaux, J.P., Elamin, Y.Y., Vijayan, R.S.K., et al. (2019) Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and En-hancer of T-DM1 Activity. Cancer Cell, 36, 444-457.e447. https://doi.org/10.1016/j.ccell.2019.09.001
|
[39]
|
Le, X., Cornelissen, R., Garassino, M., et al. (2022) Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 In-sertion Mutations after Prior Therapies: ZENITH20-2 Trial. Journal of Clinical Oncology: Official Journal of the Ameri-can Society of Clinical Oncology, 40, 710-718. https://doi.org/10.1200/JCO.21.01323
|
[40]
|
Cornelissen, R., Prelaj, A., Sun, S., et al. (2023) Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, a Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4). Journal of Thoracic Oncology, 18, 1031-1041. https://doi.org/10.1016/j.jtho.2023.03.016
|
[41]
|
Elamin, Y.Y., Robichaux, J.P., Carter, B.W., et al. (2022) Pozio-tinib for Patients with HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results from a Phase II Trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 40, 702-709. https://doi.org/10.1200/JCO.21.01113
|
[42]
|
De Grève, J., Moran, T., Graas, M.P., et al. (2015) Phase II Study of Afatinib, an Irreversible ErbB Family Blocker, in Demographically and Genotypically Defined Lung Adenocarcinoma. Lung Cancer, 88, 63-69.
https://doi.org/10.1016/j.lungcan.2015.01.013
|
[43]
|
Peters, S., Curioni-Fontecedro, A., Nechushtan, H., et al. (2018) Activity of Afatinib in Heavily Pretreated Patients with ERBB2 Mutation-Positive Advanced NSCLC: Findings from a Global Named Patient Use Program. Journal of Thoracic Oncology, 13, 1897-1905. https://doi.org/10.1016/j.jtho.2018.07.093
|
[44]
|
Dziadziuszko, R., Smit, E.F., Dafni, U., et al. (2019) Afatinib in NSCLC with HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP). Journal of Thoracic Oncology, 14, 1086-1094. https://doi.org/10.1016/j.jtho.2019.02.017
|
[45]
|
Fan, Y., Chen, J., Zhou, C., et al. (2020) Afatinib in Patients with Advanced Non-Small Cell Lung Cancer Harboring HER2 Mutations, Previously Treated with Chemotherapy: A Phase II Trial. Lung Cancer, 147, 209-213.
https://doi.org/10.1016/j.lungcan.2020.07.017
|
[46]
|
Kris, M.G., Camidge, D.R., Giaccone, G., et al. (2015) Target-ing HER2 Aberrations as Actionable Drivers in Lung Cancers: Phase II Trial of the Pan-HER Tyrosine Kinase Inhibitor Dacomitinib in Patients with HER2-Mutant or Amplified Tumors. Annals of Oncology, 26, 1421-1427. https://doi.org/10.1093/annonc/mdv186
|
[47]
|
Nagano, M., Kohsaka, S., Ueno, T., et al. (2018) High-Throughput Functional Evaluation of Variants of Unknown Significance in ERBB2. Clinical Cancer Research, 24, 5112-5122. https://doi.org/10.1158/1078-0432.CCR-18-0991
|
[48]
|
Hyman, D.M., Piha-Paul, S.A., Won, H., et al. (2018) HER Kinase Inhibition in Patients with HER2- and HER3-Mutant Cancers. Nature, 554, 189-194. https://doi.org/10.1038/nature25475
|
[49]
|
Sharma, P. and Allison, J.P. (2015) The Future of Immune Checkpoint Therapy. Science, 348, 56-61.
https://doi.org/10.1126/science.aaa8172
|
[50]
|
Pardoll, D.M. (2012) The Blockade of Immune Checkpoints in Cancer Immunotherapy. Nature Reviews Cancer, 12, 252-264. https://doi.org/10.1038/nrc3239
|
[51]
|
Catania, C., Passaro, A., Rocco, E.G., et al. (2016) Dramatic Antitumor Activity of Nivolumab in Advanced HER2-Positive Lung Cancer. Clinical Lung Cancer, 17, E179-E183. https://doi.org/10.1016/j.cllc.2016.05.004
|
[52]
|
Chuang, J.C., Stehr, H., Liang, Y., et al. (2017) ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies. Journal of Thoracic Oncology, 12, 833-842.
https://doi.org/10.1016/j.jtho.2017.01.023
|
[53]
|
Mazieres, J., Drilon, A., Lusque, A., et al. (2019) Immune Check-point Inhibitors for Patients with Advanced Lung Cancer and Oncogenic Driver Alterations: Results from the IMMUNOTARGET Registry. Annals of Oncology, 30, 1321-1328. https://doi.org/10.1093/annonc/mdz167
|
[54]
|
Guisier, F., Dubos-Arvis, C., Vinas, F., et al. (2020) Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients with Advanced NSCLC with BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018. Journal of Thoracic Oncology, 15, 628-636. https://doi.org/10.1016/j.jtho.2019.12.129
|
[55]
|
Saalfeld, F.C., Wenzel, C., Christopoulos, P., et al. (2021) Efficacy of Immune Checkpoint Inhibitors Alone or in Combination with Chemotherapy in NSCLC Harboring ERBB2 Mutations. Journal of Thoracic Oncology, 16, 1952-1958. https://doi.org/10.1016/j.jtho.2021.06.025
|
[56]
|
Chu, X., Qiang, H., Xie, M., et al. (2022) Treatment Efficacy of HER2-Mutant Lung Adenocarcinoma by Immune Checkpoint Inhibitors: A Multicenter Retrospective Study. Cancer Immunology Immunotherapy, 71, 1625-1631.
https://doi.org/10.1007/s00262-021-03100-5
|
[57]
|
Zhao, S., Xian, X., Tian, P., et al. (2021) Efficacy of Combina-tion Chemo-Immunotherapy as a First-Line Treatment for Advanced Non-Small-Cell Lung Cancer Patients with HER2 Alterations: A Case Series. Frontiers in Oncology, 11, Article ID: 633522. https://doi.org/10.3389/fonc.2021.633522
|